This summary is based on the original press release, which can be found here.
Xiogenix, a leader in biopharmaceutical technology, is excited to announce a strategic partnership with Cellipont Bioservices, a premier cell therapy Contract Development and Manufacturing Organization (CDMO). This collaboration will make Xiogenix’s Ares™ X20 fill-and-finish system available to Cellipont Bioservices’ clients, significantly enhancing the precision and efficiency of cell therapy product manufacturing processes.
The Ares™ X20 system is a state-of-the-art solution that brings precise temperature control, automated formulation, and high-throughput capabilities to cell and gene therapy production. With its ability to process multiple containers in under five minutes, minimize waste, and ensure high-quality formulations, the system sets a new standard for manufacturing efficiency and reliability. By integrating this cutting-edge technology, Cellipont Bioservices aims to accelerate time-to-market for groundbreaking therapies while maintaining the highest standards of quality and safety.
Both organizations expressed enthusiasm for the partnership. Darren Head, CEO of Cellipont Bioservices, emphasized the importance of adopting advanced technologies to enhance client offerings, while Rachel Bahr, CEO of Xiogenix, highlighted the alignment of the collaboration with Xiogenix’s mission to drive innovation in biopharmaceutical manufacturing.
This partnership represents a significant milestone for both companies and reinforces their commitment to advancing the field of cell and gene therapy production.